{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T15:49:06Z","timestamp":1781452146114,"version":"3.54.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors (ICIs) have shown efficacy for the treatment of various kinds of malignant tumors. However, ICIs can cause immune-related adverse events, such as arthritis. Nevertheless, the treatment of ICI-induced arthritis has not been established yet. Here we report a case of ICI-induced polyarthritis successfully treated using sarilumab and monitored using joint ultrasonography.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 61-year-old man presented with polyarthritis. He had been treated with nivolumab for recurrent renal cell carcinoma 11 months before. He developed ICI-induced nephritis (proteinuria and elevated serum creatinine) 3 months before, which resolved after discontinuing nivolumab for 1 month. Two months after resuming nivolumab, he developed polyarthralgia and joint swelling, which were suspected to be associated with nivolumab administration, and hence we discontinued nivolumab again. Laboratory tests revealed elevated C-reactive protein level and erythrocyte sedimentation rate, but were negative for rheumatoid factor and anti-cyclic citrullinated peptide antibody. Joint ultrasonography revealed active synovitis in several joints, but a joint X-ray revealed no bone erosion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>We diagnosed polyarthritis as ICI-induced arthritis because the findings were not typical of rheumatoid arthritis (no bone erosion and seronegativity) and the patient had already developed other immune-related adverse events (ICI-induced nephritis).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After discontinuation of nivolumab, we started treatment with 15\u200amg daily prednisolone and 1000\u200amg daily sulfasalazine, although it was ineffective. Hence, we initiated 200\u200amg biweekly sarilumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Following sarilumab administration, polyarthritis improved rapidly, and joint ultrasonography confirmed the rapid improvement of synovitis. Hence, we tapered off the glucocorticoid treatment. No recurrence of renal cell carcinoma was noted for 2\u200ayears after the initiation of sarilumab despite no anti-tumor therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Sarilumab may serve as a good treatment option for treating refractory ICI-induced polyarthritis. Joint ultrasonography may contribute to the evaluation of ICI-induced polyarthritis and monitoring the effects of treatments.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028428","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T13:07:40Z","timestamp":1642165660000},"page":"e28428","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5300-1862","authenticated-orcid":false,"given":"Kazuya","family":"Abe","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama, Kanagawa, Japan"},{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chou-ku, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama, Kanagawa, Japan"},{"name":"Sato Clinic, 4-28-5 Ebisu, Shibuya-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Yukawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Arioka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R10-20250504","first-page":"8121","article-title":"Renal biopsy for medical renal disease: indications and contraindications","volume":"23","author":"Bandari","year":"2016","journal-title":"Can J Urol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"R12-20250504","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice: ACR RA disease activity measures recommendations","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"(5 suppl 39)","key":"R14-20250504","first-page":"S100","article-title":"The simplified disease activity index (Sdai) and the clinical disease activity index (Cdai): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/ard.2004.023929","article-title":"Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography","volume":"64","author":"Naredo","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R19-20250504","first-page":"3833","article-title":"TNF-\u03b1 is critical for antitumor but not antiviral T cell immunity in mice","volume":"117","author":"Calzascia","year":"2007","journal-title":"J Clin Invest"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.smim.2014.01.007","article-title":"The IL-6 feed-forward loop: a driver of tumorigenesis","volume":"26","author":"Chang","year":"2014","journal-title":"Semin Immunol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","article-title":"Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma","volume":"15","author":"Shinriki","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0161-5890(02)00210-9","article-title":"The two faces of IL-6 on Th1\/Th2 differentiation","volume":"39","author":"Diehl","year":"2002","journal-title":"Mol Immunol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (Monarch): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/art.10784","article-title":"Diagnostic value of high-resolution B-mode and Doppler sonography for imaging of hand and finger joints in rheumatoid arthritis","volume":"48","author":"Weidekamm","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/14397595.2014.974305","article-title":"A novel 8-joint ultrasound score is useful in daily practice for rheumatoid arthritis","volume":"25","author":"Yoshimi","year":"2015","journal-title":"Mod Rheumatol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/rheumatology\/kex470","article-title":"Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events","volume":"57","author":"Albayda","year":"2018","journal-title":"Rheumatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:24:42Z","timestamp":1746332682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028428"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028428","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"assertion":[{"value":"2021-08-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}